Clinical trials: Type 1 Diabetes Mellitis
Type 1 Diabetes Mellitus, T1D
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103.
- Conditions
- Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus
- Trial name
- NCT06783309
- Testing
- CNP-103
- Where
- 45 sites in United States
- Volunteers
- 72 people
- Sponsor
- COUR Pharmaceutical Development Company, Inc.
Type 1 Diabetes Mellitis
Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State
This trial intends to investigate the pharmacodynamics, pharmacokinetics, safety, and tolerability of insulin GZR33 (hereafter referred to as GZR33) and estimate its potency in comparison with insulin degludec.
- Trial name
- NCT07242664
- Testing
- GZR-33
- Where
- 2 sites in Germany
- Volunteers
- 12 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Type 1 Diabetes Mellitis
Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients
The goal of this clinical trial is to demonstrate the non-inferior immunogenicity of GP40321 compared to Apidra® SoloStar® at a concentration of 100 U/mL in type 1 diabetes mellitus patients.
- Trial name
- NCT07070752
- Testing
- GP40321, Apidra® SoloStar®, RinGlar®
- Where
- 17 sites in Russia
- Volunteers
- 224 people
- Sponsor
- Geropharm
Diabetes Mellitis Type 2
A Study to Characterize the Pharmacokinetics/Pharmacodynamics and Effect of Food of DA-1229 in Healthy Male Subjects
This is a dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation study. The study is designed to describe the relationship between multiple doses and pharmacokinetic/pharmacodynamic…
- Trial name
- NCT00961025
- Testing
- DA-1229
- Where
- South Korea
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Dong-A Pharmaceutical Co., Ltd.